Canaccord Pounds the Table on Sunshine Heart Inc
Canaccord Genuity analyst Jason Mills was out pounding the table on Sunshine Heart Inc (NASDAQ:SSH) Thursday, reiterating a Buy rating and a $7.50 price target, which represents a potential upside of 82.5% from where the stock is currently trading.
Mills noted, "We would be buyers of SSH common, which we think could move higher once the US trial “pause” is lifted and enrollment re-accelerates. We continue to believe SSH offers investors the opportunity to participate in a nascent growth company that is commercializing potentially disruptive technology for the treatment of moderate heart failure. We remain positive on the long-term prospects for SSH's differentiated technology in the treatment of Class III heart failure; thus, we maintain our BUY rating."
According to TipRanks.com, which measures analysts' and bloggers' success rate based on how their calls perform, analyst Jason Mills has a total average return of 4.3% and a 56.9% success rate. Mills has a -28.3% average return when recommending SSH, and is ranked #943 out of 3533 analysts.